25 results about "Hepatic Diseases" patented technology

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

This invention relates to a composition for improving alcoholic liver damage, belonging to the field of health product technology. This application provides the use of rhodioloside and lactose-N-trisaccharide in the prevention and / or inhibition of alcoholic liver disease. This application also provides a composition of human lactose oligosaccharides and rhodioloside. The compositions described in this application can prevent the occurrence of alcoholic liver disease or inhibit its further deterioration. This application provides a green, safe, and healthy composition, offering an ideal composition for protecting human health.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

This invention provides an application of tartary buckwheat antioxidant peptide as a PPARα agonist. The tartary buckwheat antioxidant peptide (SEQ ID NO:1) is used to prepare a PPARα agonist, and this tartary buckwheat antioxidant peptide is used to prepare a drug for improving metabolic dysfunction-related fatty liver disease (MASLD). The tartary buckwheat antioxidant peptide of this invention provides a new drug candidate for improving MASLD and has broad clinical application prospects.

This invention relates to pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease.

This invention discloses a risk prediction device and storage medium for metabolic-associated fatty liver disease in children or adolescents. The two-stage cascaded screening strategy and model of this invention provide a highly accurate, accessible, and scalable solution for the early identification of metabolic-associated fatty liver disease in children or adolescents. This invention utilizes different anthropometric data to identify high-risk groups in routine school physical examinations, followed by further screening using a comprehensive serological index at community health centers, thereby achieving accurate diagnosis of metabolic-associated fatty liver disease and providing clinicians with a non-invasive auxiliary diagnostic tool that combines high precision, high accuracy, and broad accessibility.

The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1 / glucagon receptor agonist activity in the prevention and / or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non- alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and / or cirrhosis.

Use of a RASP inhibitor in the treatment of chronic cough, asthma and alcoholic liver disease. The RASP inhibitor includes a compound represented by formula (II) or a pharmaceutically acceptable salt or crystal form thereof. And has good efficacy in animal model experiments of diseases such as chronic cough, asthma and alcoholic liver disease.

This invention discloses a composition for improving metabolic syndrome, its preparation method, and its application. The composition for improving metabolic syndrome comprises privet fruit, honeysuckle, wolfberry fruit, kudzu root, and astragalus root. The medicinal materials used in the formulation involved in this invention are all traditional Chinese medicinal herbs that are also used in food, exhibiting extremely high safety and definite efficacy. two and db In mice, it demonstrated clear efficacy in lowering blood sugar and improving metabolic syndrome, comparable to metformin, and even superior to metformin in some lipid parameters. Further mechanistic studies showed that the optimized formulation 3 can exert a synergistic effect by regulating multiple metabolic pathways, and can be used to regulate metabolic-related diseases such as diabetes, fatty liver, alcoholic liver disease, and dyslipidemia.

The application discloses a blood sample-based 1 The application discloses a method for constructing a metabolic related fatty liver disease typing model of H-NMR metabolomics, a typing system, a method and application. 1 The application screens 2 clinical variables and 10 H-NMR metabolic variables based on an NMR metabolomics analysis platform and a machine learning method, and establishes a scoring formula of 5 metabolic pathways by using a logistic regression model. Based on the scoring of the 5 metabolic pathways, unsupervised clustering is performed by using K-means clustering analysis, MASLD patients are divided into 3 categories, and a new disease typing model is established, and good verification is obtained in a verification queue. The 3 disease typing methods provided by the application have significant differences in metabolic disease new-onset risk and death risk and fat-reducing treatment response. The body fluid sample required by the typing system or method is convenient to extract and causes less pain to patients, and the application provides a new direction for clinical outcome prediction and clinical treatment of MASLD.

The technical problem of this invention is to provide pharmaceutical compositions and combinations of agents capable of preventing and / or treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. This invention provides a combination of a peroxisome proliferator-responsive receptor (PPAR) α agonist and a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the prevention and / or treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

This invention provides a fermenting *Lactobacillus mucinus* strain that can accelerate alcohol metabolism and improve hangover symptoms, along with its applications. This strain exhibits high safety, lacking resistance genes and pathogenic virulence genes, and demonstrates strong tolerance to bile salts, artificial gastric juice, and artificial intestinal juice. The bacterium possesses strong antioxidant capabilities, exhibiting potent scavenging abilities against ABTS, DPPH, and hydroxyl radicals. This fermenting *Lactobacillus mucinus* can increase the alcohol dehydrogenase content in a mouse model of alcoholic liver disease, demonstrating significant application value in antioxidation, alcohol detoxification, and hangover prevention. Furthermore, this bacterium can produce melatonin and convert NR to niacin.

The application provides application of FBXO22 in diagnosis and treatment of non-alcoholic fatty liver disease, discloses that FBXO22 is highly expressed in non-alcoholic fatty liver disease, and verifies that reducing the expression level of FEXO22 can delay the progress of non-alcoholic fatty liver disease, reduce liver inflammation and slow down liver lipid accumulation. FBXO22 can be used for diagnosis and treatment of non-alcoholic fatty liver disease, screening of candidate drugs for non-alcoholic fatty liver disease, and also can be used for efficacy evaluation, research and revelation of the pathogenesis of non-alcoholic fatty liver disease. The application has important significance for clinical research of non-alcoholic fatty liver disease.

The application discloses Bacteroides multipara and application thereof for relieving metabolic dysfunction related fatty liver disease, and belongs to the technical field of microorganisms. Phocaeicola dorei The Bacteroides multipara N02 can inhibit the increase of liver and the increase of liver weight / body weight of a mouse with metabolic dysfunction related fatty liver disease without affecting the food intake, can regulate the lipid metabolism disorder of the mouse with metabolic dysfunction related fatty liver disease and relieve the liver tissue damage, and can improve the intestinal barrier function of the mouse with metabolic dysfunction related fatty liver disease. The Bacteroides multipara N02 has a very wide application prospect when used for preparing a medicine composition for relieving metabolic dysfunction related fatty liver disease and a fermented food.

The application discloses STUB1 application of the gene or the STUB1 protein coded by the gene in the preparation of a medicine for preventing or treating obesity and related metabolic diseases STUB1 The application first proves that the gene and the coded protein are key target points for regulating fat metabolism, and the bidirectional regulation value is determined: on one hand, inhibition of STUB1 can significantly up-regulate the CIDEC protein level, promote normal fat storage of adipocytes, and improve insulin resistance and non-alcoholic fatty liver disease; on the other hand, activation of STUB1 can accelerate the degradation of CIDEC, inhibit lipid storage, realize the effect of reducing fat, and provide a brand-new intervention target point and treatment idea for metabolic diseases such as obesity, type 2 diabetes and dyslipidemia.

This invention provides a probiotic symbiotic biofilm and its application in the preparation of products for the prevention or adjunctive treatment of alcoholic liver disease, relating to the field of biomaterials technology. The probiotic symbiotic biofilm is composed of *Lactobacillus rhamnosus* (…). Lactobacillus rhamnosus LRa05 and Bifidobacterium lactis ( Bifidobacterium lactis The above two microorganisms were prepared using BLa80. Under co-culture conditions, they can form a dense symbiotic biofilm. The two strains are evenly distributed and intertwined within the biofilm, forming a thicker and more stable three-dimensional structure than a single strain. This symbiotic biofilm structure endows the probiotics with stronger environmental tolerance and intestinal adhesion ability, laying the foundation for their colonization and sustained function in the intestine. It can not only significantly improve alcohol-induced intestinal barrier damage, but also effectively intervene in alcoholic liver disease, providing a new application scenario for the two strains.

Screening and risk-stratification of patients at risk for developing liver disease, such as non-alcoholic fatty liver disease (“NAFLD”), among others, is achieved by applying an optimized set of patient health data features to a suitably trained machine learning algorithm or model. The machine learning model outputs NAFLD risk score data that quantify or otherwise indicate a risk of the patient developing NAFLD based on features present in their patient health data. The NAFLD risk score data can be further analyzed to risk stratify the patient and assist with determining next steps in the healthcare workflow for the patient.

The present disclosure relates to compounds of the general formula (I):wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

This application proposes the use of ACSL4 and / or TfR1 genes as targets in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease (NAFLD) under hypoxic conditions. The drugs include resveratrol, which inhibits hypoxia-induced ferroptosis by downregulating the expression of key ferroptosis genes ACSL4 and TfR1. Compared with existing technologies, this application has the following advantages: This application reveals the antioxidant, anti-inflammatory, liver-damage-alleviating, and lipid metabolism-regulating effects of resveratrol using a hypoxic NAFLD model. Pharmacodynamic studies targeting resveratrol demonstrate that ACSL4 and TfR1 have a significant ability to regulate ferroptosis and may affect the progression of NAFLD, which is of great significance for the development of subsequent related drugs and the rational use of medications at high altitudes.

This invention relates to a traditional Chinese medicine preparation for treating type 2 diabetes and its preparation method. The traditional Chinese medicine preparation of this invention has a simplified formula, definite clinical efficacy, and the function of soothing the liver and strengthening the spleen. In clinical application, this traditional Chinese medicine preparation also has a good therapeutic effect on metabolic-related fatty liver disease. Clinically, it has shown significant clinical efficacy in patients with T2DM complicated with MAFLD diagnosed as liver stagnation and spleen deficiency. The preparation process of this invention is simple, the quality is stable, and it has broad prospects for industrial application.

The application discloses an antisense oligonucleotide conjugate targeting Stk25 mRNA and application thereof, and belongs to the technical field of biological medicines. The antisense oligonucleotide conjugate comprises: 1) an antisense oligonucleotide with a length of 16 nucleotides, wherein the oligonucleotide sequence is GATCTTGATGGCCACC, as shown in SEQ ID NO:1; and 2) a trivalent GalNAc conjugation part covalently connected to the oligonucleotide. The application provides an antisense oligonucleotide conjugate targeting Stk25 mRNA, and experiments prove that the antisense oligonucleotide conjugate can realize liver-specific, high-efficiency and long-acting STK25 knockdown in vivo, and simultaneously improve pathological indexes such as lipid accumulation, abnormal blood glucose and obesity of body weight related to MASLD, thereby providing a novel gene therapy drug with high targeting, long-lasting curative effect and high safety for the treatment of metabolic related fatty liver disease.

This invention provides the application of IDH1 Kcr in the diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD). The study shows that IDH1 Kcr levels are downregulated in NAFLD, indicating that IDH1 Kcr can serve as a biomarker for the diagnosis and / or prognostic analysis of NAFLD. By monitoring IDH1 Kcr levels, the diagnosis, early prevention, and prognostic prediction of NAFLD can be achieved, providing an important reference for clinical diagnosis and treatment plans.

This invention discloses a strain of Enterobacter AF31-8 and its applications, belonging to the field of microbial pharmaceutical technology. This strain was deposited on March 10, 2026, at the Guangdong Provincial Microbial Culture Collection Center, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC No:67911, and classified as follows: Bacteroides intestinalis This invention demonstrates the effectiveness of Enterobacter bacteriophages (Enterobacteroides) using a mouse model. Bacteroides intestinalis It can activate specific metabolic protective pathways: the strains promote the biosynthesis of arginine and its metabolic derivatives in the intestine, inhibit the expression of genes related to de novo fat synthesis in the liver, reverse lipid accumulation at the source, and alleviate the progression of metabolic dysfunction-related fatty liver disease induced by a high-fat diet.